entertainment -WSS

entertainment

author：focus 2025-09-29 13:30:40 - browse：3966

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： CDC wastewater surveillance dashboard to track bird flu hotspots

WSS

It's time to get medical device identifiers over the finish line

Leqembi, other new Alzheimer’s drugs require better biomarkers

How to improve immunocompromised access to mAb treatments

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

NIH fellows want a pay raise. Will that mean less money for grants?

NIH fellows want a pay raise. Will that mean less money for grants?

entertainment

entertainment

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Elevance, private equity launch primary care company

Heart attack and stroke risk calculators need revising

Making AI in medicine accessible to smaller, and rural hospitals

Medicare details structure of new drug price negotiation program

Study: Pain burden is higher in Black NFL players than white ones

Wildfire smoke exposes gaps in outdoor worker protections

What nurses really want: sufficient staffing for patient care

Cancer drug shortages should be causing more outrage

H5N1 bird flu: what we're starting to learn about infection in cows

explore

Beach reads and more: STAT's 2023 summer book list

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Why 40% Americans with Parkinson’s don’t see a neurologist

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Charles Manson follower Leslie Van Houten released from prison after 53 years

knowledge

leisure time

explore

leisure time